Biosynth Carbosynth and Shengquan acquire Chinese plant

With this acquisition, Biosynth Carbosynth’s and Shengquan’s joint venture Carbotang expands its production capacities significantly

Biosynth Carbosynth, a life sciences reagents and custom synthesis and manufacturing services company, and Jinan Shengquan Group Share-Holding Co. have announced their acquisition of Kexing Biopharmaceutical’s raw material factory in Jinan, China.

With this acquisition, Biosynth Carbosynth’s and Shengquan’s joint venture Carbotang expands its production capacities significantly. The more than 30,000 sqm property contains a factory building on 5 floors, a demo workshop and a large warehouse including dangerous material storage. The expansion through a further production site now allows the group more flexibility and larger production volumes together with an increased production reliability, the company says.

Urs Spitz, CEO of Biosynth Carbosynth said: “We are delighted to be further expanding our manufacturing operations and hugely successful joint venture. With this strategic acquisition we can continue to deliver our enormous range of products at increasing scales, with unrivalled expertise in complex organic chemistries.”

Companies